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Infection with human immunodeficiency virus (HIV) has been associated with increased rates of single-
and multidrug-resistant (MOR) tuberculosis in the New York City area. In order to examine the rela-
tionship of HIV infection to drug-resistant tuberculosis in other selected regions of the United States,
we established a registry of cases of culture-proven tuberculosis. Data were collected from sites par-
ticipating in an NIH-funded, community-based HIVclinical trials group. Allcases of tuberculosis, regard-
less of HIV status, which occurred between January 1992 and June 1994 were recorded. Overall, 1,373
cases of tuberculosis were evaluated, including 425 from the New York City area, and 948 from seven
other metropolitan areas. The overall prevalence of resistance to one or more drugs was 20.4%, and
5.6% of isolates were resistant to both isoniazid and rifampin (MOR). In the New York City area, HIV-
infected patients were significantly more likely than persons not known to be HIV-infected, to have
resistance to at least one drug (37% versus 19%) and MDR(19% versus 6%). In other geographic areas,
overall drug resistance was 16%, and only 2.2% of isolates were MOR. In multiple logistic reqresslon
analyses, HIV infection was shown to be a risk factor for drug-resistant tuberculosis, independent of
geographic location, history of prior therapy, age, and race. We concluded that HIV infection is as-
sociated with increased rates of resistance to antituberculosis drugs in both the New York City area
and other geographic areas. MORtuberculosis is occurring predominantly in the New York City area
and is highly correlated with HIV infection. Gordin FM, Nelson ET,Matts IP, Cohn Dl, Ernst I, Bena-
tor D, Besch Cl, Crane lR, Sampson IH, Bragg PS, EI-Sadr W, and the Terry &elm Community
Programs for Clinical Research on AIDS. The Impact of human Immunod~flclencyvirus Infec-
tion on drug-resistant tuberculosis. AM J RESPIR CRIT CARE MED 1996;154:1478-1483.
The association of human immunodeficiency virus (HIV) infec-
tion with the resurgence of tuberculosis in the United States has
been welldocumented (1-3). HIV-infected persons are much more
likelyto experience reactivation tuberculosis than immunocompe-
tent hosts, with rates of active tuberculosis occurring in 7 to 10070
per year of dually infected patients (4-6). In addition, primary
progression from tuberculosis infection to disease occurs more
frequently and more rapidly in HIV-infected persons (7-9). Re-
cent studies have documented that up to 40070 of tuberculosis
in this population may be due to recent acquisition of the organ-
ism (10, 11).
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The increase in numbers of patients with both HIV infection
and tuberculosis has been accompanied by a concern about in-
creasing rates of resistance to antituberculosis drugs in this popu-
lation. Outbreaks of multidrug-resistant (MDR) tuberculosis in
HIV-infected patients have been reported from several hospitals
in the New York City area (7, 12, 13). A survey of all isolates
of Mycobacterium tuberculosis obtained in New York City dur-
ing a l-rno period in 1991 demonstrated HI V-infected persons
to be twice as likely to have drug-resistant isolates, and over six
times more likely to have MDR tuberculosis than persons with
no documented HIV infection (14).While there have been reports
of MDR tuberculosis outbreaks in HIV-infected patients in other
cities (9, 15), there has been no survey of the overall impact of
HIV infection on tuberculosis drug resistance in the United States.
We established a tuberculosis registry to collect information
on patients with culture-proven tuberculosis from selected geo-
graphic regions throughout the United States. These data were
evaluated to assess the characteristics of these cases, define re-
sistance patterns, and determine the impact of HIV infection and
other sociodemographic factors on the prevalence of drug-resis-
tant tuberculosis.
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METHODS
A tuberculosis registry was developed using participating sites of the
Terry Beirn Community Programs for Clinical Research on AIDS
(CPCRA). The CPCRA is a network of primary care providers located
in private practice, hospitals, and clinics providing HIV-infected per-
sons access to clinical trials, with a special emphasis on the recruitment
of women, injecting drug users, African-Americans, and Latinos. These
providers also care for a large number of HI V-negative patients; and
for the purpose of this registry, participating sites collected data on all
available tuberculosis cases seen at their site, regardless of HIV status.
Data were obtained by chart abstraction from culture-confirmed tu-
berculosis cases whose final culture and drug susceptibility results be-
came available between January I, 1992 and June 30, 1994. Only those
patients 13yr of age or older with available antimicrobial susceptibility
results are included in this report. Information collected included demo-
graphic data, tuberculosis risk factors, HIV risk behaviors, HIV serosta-
tus, and history of prior tuberculosis treatment. As the information was
obtained by chart abstraction, data are missing for some variables for
some patients.
Only initial culture specimens collected before or at the initiation
of antituberculous therapy were used to determine drug susceptibility
patterns. Participating units used local laboratories for the isolation and
identification of organisms, as wellas for determination of in vitro drug
resistance. The site from which the isolates were obtained and the results
of antimicrobial susceptibility tests were recorded. Patients were counted
as having tuberculosis resistant to a particular drug if any of their initial
isolates were resistant to that drug. Patients were defined as having an
organism susceptible to a drug if all of their initial isolates were suscep-
tible to that drug.
Patients were assigned unique case numbers and all data were trans-
mitted to the national registry with no linkage between the case number
and the patient's name. As a result, there was anonymity of all study
participants, thus, no informed consent was required. This study was
approved by the institutional review boards of all participating sites.
Fisher's exact tests and chi-square tests were used to assess the statisti-
cal significance of differences between proportions. Stepwise logistic
regression was used in an iterative manner to asses the independent fac-
tors, and the odds ratios (OR), related to drug resistance. A forward/
backward selection process was used. Because there was casewise dele-
tion of each patient with any missing variable, a forward selection pro-
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cess was run and the least significant variable was deleted (backward)
from the list of variables. The process was then repeated on the usually
increased number of cases. Iterations of this process stopped when no
further variable could be retained with p <0.10. The following variables
were initially included in the logistic regression: gender, age, race, sex-
ual orientation, place of birth, homelessness, unemployment, alcohol
use, street drug use, prior therapy for tuberculosis, intravenous (IV) drug
use, HIV status, and geographic area. For HIV status, an indicator vari-
able for unknown HIV status relative to negative HIV status was in-
cluded to avoid casewise deletion of those with unknown status. As long
as the HIV-positive variable had a p < 0.10, this variable was also in-
cluded. There were four race categories (African-American, Latino, Asian,
and White/Other) and three age groups (13 to 35, 36 to 50, and> 50
yr). Additional analyses were done using classification and regression
trees (16) to explore the data for additional relationships including in-
teractions not identified by the logistic regression. No important addi-
tional relationships were found. For multivariate analysis, only the logistic
regression results are reported. All p values are two-sided. A p value less
than 0.05 was considered statistically significant. No adjustments for
multiple comparisons were made.
RESULTS
Thirteen units from eight metropolitan areas contributed 1,465
tuberculosis cases for the registry, of whom 92 cases were ex-
cluded because susceptibility testing was either not done or was
nonretrievable. Of the remaining 1,373 cases, five units from
northern New Jersey, Manhattan, Brooklyn, and the Bronx ac-
counted for 425 cases from the "New York City area." Two units
from Detroit, MI, and one each from Washington, DC, Denver,
CO, Chicago, IL, New Orleans, LA, Richmond, VA, and Port-
land, OR, contributed a total of 948 cases from the "outside New
York City" area. Pulmonary tuberculosis alone was the site of
infection in 1,058 patients, extrapulmonary disease alone was
present in 192, and both pulmonary and extrapulmonary dis-
ease were present in 123 individuals.
Demographic data, tuberculosis and HIV risk factors, and
HIV serostatus are shown for the New York City area and out-
side New YorkCity area groups in Table 1. Individuals with tuber-
TABLE 1
DEMOGRAPHIC, BEHAVIORAL, AND SELECTED CLINICAL CHARACTERISTICS
OF PATIENTS WITH TUBERCULOSIS
New York City Area Outside New York City Area
(n = 425) (n = 948)
% with % with
Characteristic N* Characteristic N* p Value"
Male 66.6 425 71.2 947 0.098









Homosexual/Bisexual 12.7 354 27.1 295 < 0.001
Born in United States 79.0 305 69.1 764 < 0.001
Homeless'[ 13.0 394 3.7 755 < 0.001
Unemployedf 63.9 330 19.3 679 < 0.001
Excessive use of alcohol+ 35.1 379 17.7 690 < 0.001
Used street drugs+ 44.1 404 9.9 576 < 0.001
Prior TB therapy 18.8 404 14.7 770 0.079
Used IV drugs 47.0 396 19.8 643 < 0.001
HIV-positive 78.7 324 29.0 617 < 0.001
* Number of patients with known data for each characteristic.
t p Value for difference between New York City area and outside New York City.
:j: For more than 1 yr.
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TABLE 2
RELATIONSHIP OF HIV STATUS TO ANTITUBERCULOSIS
DRUG RESISTANCE
Pan Mono Resistant
HIV Status Susceptible* Resistant'[ to ~ 2 Drugs
New York City area
Positive 161 (63.1%)=1: 32 (12.6%) 62 (24.3%)
Negative 56 (81.2%) 9 (13.0%) 4 (5.8%)
Unknown 83 (82.2%) 11 (10.9%) 7 (6.9%)
Outside New York City area
Positive 153 (85.5%) 20 (11.2%) 6 (3.4%)
Negative 364 (83.1%) 53 (12.1%) 21 (4.8%)
Unknown 276 (83.4%) 34 (10.3%) 21 (6.3%)
* Susceptible to all drugs for which susceptibility testing was performed.
t Resistant to only one of the drugs for which susceptibility testing was performed.
:\: p = 0.001 for comparison of resistance between Hlv-positive and Hlv-neqative per-
sons.
culosis from the New York City area were more likely to be less
than 51 yr old and have a history of being homeless, being un-
employed, using alcohol to excess, and using IV or street drugs,
than persons from the non-New York City area. A history of
prior antituberculosis therapy was similar in both areas. Of 324
patients with known HIV serostatus in the New York City area,
255 (79010) were positive, significantly higher than the rate of HIV
infection reported in tuberculosis patients from other areas (178
of 617 [29010)).
As shown in Table 2, patients from the New York City area
were more likely to have drug-resistant isolates (29010) than pa-
tients from other areas (16010) (p < 0.(01). In the New York City
area, individuals with HIV infection were more likely to have
drug-resistant isolates than HIV-negative persons, whereas out-
side of the New York City area, HIV infection appeared to have
no impact on overall tuberculosis drug resistance. Of all patients
with drug-resistant strains, a higher percentage were resistant to
two or more drugs in the New York City area (73 of 125 [58010))
than in the non-New York City area (48 of 155 [31010)) (p <0.(01).
Of patients with isolates resistant to two or more drugs, 58 of
73 (79010) in the New York City area were resistant to both isonia-
zid and rifampin (MDR). Outside of the New York City area,
resistance to both isoniazid and rifampin occurred in only 21 of
48 (44010) patients with isolates resistant to two or more drugs.
Patients with MDR tuberculosis in the New York City area were
predominantly HIV-infected (49 of 58), whereas in other areas,
MDR tuberculosis occurred primarily in Asians born outside of
the United States, in African-Americans (17 of 21), and in indi-
viduals who had received prior tuberculosis therapy (14 of 21),
and was not univariately associated with HIV infection.
The impact of HIV infection on resistance to individual an-
tituberculosis drugs is shown in Table 3. In the New York City
area, HIV-infected persons had higher rates of resistance to isonia-
zid, rifampin, ethambutol, and streptomycin and were more likely
to have MDR tuberculosis. In addition, the rate of resistance to
pyrazinamide was almost twice as high in HIV-infected persons,
although this was not statistically significant. Outside of the New
York City area, the rate of resistance to antituberculous drugs
did not differ by HIV status.
The univariate relation of a specific demographic, tuberculo-
sis, and HIV risk factors to antituberculosis drug resistance rates
is shown in Table 4. In the New York City area, only HIV infec-
tion and a history of prior tuberculosis therapy were significantly
associated with a higher rate of drug resistance. Outside of the
New York City area, being foreign-born or Asian, having a his-
tory of prior treatment, and being of younger age were signifi-
cantly associated with increased drug resistance. Other socioeco-
nomic factors such as being homeless, being unemployed, and
using alcohol to excess were not found to be associated with drug
resistance.
In the New York City area, HIV-infected patients were more
likely to have drug resistance regardless of their history of prior
tuberculosis, although there was only power to demonstrate
statistical significance in individuals who had not been treated
before for tuberculosis (32.3010 of HIV-infected versus 17.2010 of
HI V-negative patients without prior treatment had tuberculosis
drug resistance, p = 0.03). Outside of the New York City area,
HIV infection also appeared to be a risk factor for drug resis-
tance among U.S.-born individuals. Of U.S.-born persons living
in the non-New York City area, 18.8% of HIV-positive persons
had resistant isolates compared with only 11.1010 of HIV-negative
persons (p = 0.06).
Variables found to be independently associated with antituber-
culosis drug resistance were prior history of tuberculosis ther-
apy, Asian race, younger age, living in the New York City area,
and known infection with HIV (Table 5). Race categories were
similar and thus were combined as were the two lower age cate-
gories.
DISCUSSION
This study is the first to examine the impact of HI V infection
on rates of tuberculosis drug resistance in selected geographic
regions throughout the United States. Our patient population
TABLE 3
PROPORTION OF PATIENTS WITH ISOLATES RESISTANT TO INDIVIDUAL
ANTITUBERCULOSIS DRUGS BY GEOGRAPHIC AREA AND HIV STATUS
INH and
INH RIF EMB PZA STM RIF
---
HIV Status n* % n % n % n % n % n %
New York City area
Positive 254 29.9t 252 22.6* 253 10.2t 190 12.1 231 15.6t 252 19.4t
Negative 69 13.0 69 5.8 69 1.5 49 6.1 68 5.9 69 5.8
Unknown 101 14.9 101 5.9 100 5.0 75 5.3 101 5.9 101 5.0
Non-New York City area
Positive 179 8.4 179 3.9 179 1.7 90 3.3 174 3.5 179 2.8
Negative 438 9.8 437 2.1 438 1.8 202 3.0 432 4.9 473 1.4
Unknown 330 10.6 330 3.9 330 1.5 145 0.7 322 8.1 330 3.0
Definition of abbreviations: INH = isoniazid; RIF= rifampin; EMB = ethambutol; PZA = pyrazinamide; STM = streptomycin.
* n = number of patients' isolates tested for resistance; % = percent of those tested which were resistant.
t p < 0.05 for comparison between HIV+ and HIV-.
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TABLE 4
PROPORTION OF PATIENTS WITH ISOLATES WITH ANTITUBERCULOSIS DRUG
RESISTANCE BY GEOGRAPHIC AREAS AND OTHER FACTORS
New York City Area Outside New York City Area
n % with Resistance n % with Resistance
Gender
Male 283 30.7 674 16.2
Female 142 26.8 273 16.5
Race
Black 251 27.5 472 14.7
Latino 136 30.9 77 14.3
Asian 1 100.0 119 38.7*
Other 35 37.1 270 10.7
Age, yr
13-35 135 24.4 278 23.0*
36-50 219 34.3 341 15.5
51 + 71 23.9 329 11.6
Homosexual/Bisexual
Yes 45 33.3 80 15.0
No 309 25.9 215 13.0
Born in United States
Yes 241 32.4 528 13.6*
No 64 23.4 236 26.7
Homeless t
Yes 51 35.3 28 14.3
No 343 28.6 727 17.3
Unernployed l'
Yes 211 32.2 131 17.6
No 119 27.7 548 16.2
Excessive use of alcohol"
Yes 133 29.3 122 15.6
No 246 28.9 568 15.7
Used street drugs
Yes 178 33.1 57 22.8
No 226 27.0 519 13.7
Used IV drugs
Yes 186 33.9 127 17.3
No 210 25.2 516 14.9
Prior TB therapy
Yes 76 44.7* 113 36.3*
No 328 25.6 657 15.3
HIV-positive
Yes 254 36.9* 179 14.5
No 67 18.8 438 16.9
* p < 0.05.
t For more than 1 yr.
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was not selected to reflect a sampling of all tuberculosis cases
in those regions, and may reflect unknown biases that have oc-
curred owing to characteristics of patients who use the facilities
participating in this study. These biases may have included an
overreporting of HIV-positive patients, or possible distortions
due to different approaches to case finding used in different lo-
cations, and the data should be interpreted in this light. The demo-
graphics of our population do, however,mirror the demographics
of tuberculosis in the United States as a whole, which is occur-
ring predominantly in large urban areas, with overrepresenta-
tion of racial minorities, socioeconomically disadvantaged per-
sons, HIV-infected persons, and the foreign-born (3).
In the New York City area, resistance to at least one of the
primary tuberculosis drugs occurred in 37070 of HIV-positive pa-
tients and 18% of persons with unknown or negative HIV sta-
tus. Even more disturbing was that resistance to the two most
effectivedrugs, isoniazid and rifampin occurred in 30% and 23%,
respectively, of HIV-infected persons, and was also substantial
in HIV-negative individuals. When isolates from HIV-infected
persons in the New YorkCity area were resistant, they were more
likely to be resistant to multiple drugs (62 of 94 patients) than
those from non-HIV-infected patients, with 49 HIV-infected pa-
tients resistant to both isoniazid and rifampin.
Our study showed that outside of the New York City area,
16% of patients were resistant to at least one drug. While the
prevalence of resistance to isoniazid was 10%, the prevalence of
resistance to rifampin and pyrazinamide was only 3% for each
TABLE 5
CHARACTERISTICS ASSOCIATED WITH DRUG RESISTANCE
BY LOGISTIC REGRESSION
Characteristics Odds Ratio 95% CI P Value
HIV-negative 1.00
HIV-positive 1.76 (1.81,2.62) 0.005
HIV unknown 1.15 (0.77, 1.71) 0.495
History of prior TB treatment 2.88 (2.03, 4.09) < 0.001
Age';;; 50 yr 1.54 (1.05, 2.27) 0.026
Asian 4.58 (2.88, 7.29) < 0.001
New York City area 1.85 (1.31,2.61) < 0.001
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drug. Resistance to two or more drugs was low (5%), and com-
bined resistance to isoniazid and rifampin (MDR) was unusual
(2.2070). Most patients with MDR tuberculosis had received prior
tuberculosis treatment, were born outside the U.S., and were not
known to be HIV-infected.
While HIV infection was associated with an almost twofold
increased risk of drug resistance in the New York City area, our
ability to evaluate the impact of HIV infection on drug resis-
tance in the non-New York City area was hindered by a high
proportion of foreign-born persons with tuberculosis and a rel-
atively low proportion of persons with HIV infection reported
from those areas. The overall prevalence of drug resistance found
in foreign-born individuals living outside the New YorkCity area
was 27070. Most of these individuals wereAsian and werereported
from the Portland, OR site. When only U.S.-born individuals
wereevaluated, it became evident that HIV infection was, in fact,
a risk factor for drug resistance outside of the New York City
area: 19% of U.S.-born HIV-infected patients were resistant to
at least one antituberculosis drug, versus 11010 of U.S.-born pa-
tients not known to be HIV-infected (p = 0.055). Additionally,
HIV infection was shown in logistic regression to be indepen-
dently associated with drug resistance even after taking into ac-
count geographic area, Asian race, and history of prior treat-
ment, providing additional evidence that HIV is an important
risk factor for drug resistance in all areas of the country.
Caution should be used in interpreting Asian race as being
associated with increased drug resistance. This was highly related
to being born outside of the United States and thus may repre-
sent being foreign-born rather than Asian race. Use of street drugs
or injected drugs was not selected in the regression even though
in univariate analyses these variables appeared to have a border-
line relationship to resistance. It may be that these variables are
related to drug resistance, but that in this data set other factors
were found to be more important.
Prior therapy with antituberculosis drugs is a known predic-
tor of acquired drug resistance (17-18). In both the New York
City area and elsewhere, patients with a history of prior therapy
were almost twice as likely to have resistant isolates as persons
without prior therapy. For persons from areas other than New
York City, we found being foreign-born to be an additional risk
factor for drug resistance. Socioeconomic factors (including a
history of unemployment, homelessness, and excessiveuse of al-
cohol) that have been associated with high rates of tuberculosis
and noncompliance with treatment (3, 18, 19)werenot associated
with an increased risk of drug resistance in any region.
Of the national surveys of tuberculosis drug resistance in the
last decade, none have focused on the impact of HIV infection
(17, 18, 20). The most recent Centers for Disease Control and
Prevention (CDC) survey of M. tuberculosis isolates from the
first quarter of 1991 demonstrated the prevalence of resistance
to at least one drug to be 14.2%, and that 3.5% of all isolates
were resistant to both isoniazid and rifampin (MDR) (18). Drug
resistance was approximately four times more frequent in iso-
lates from New York State than for the other participating sites
combined; HIV serostatus was not reported. In our data, which
examined isolates obtained from 1992 to 1994, the overall preva-
lence of drug resistance was 20.4%, and MDR strains accounted
for 5.6% of all isolates. A direct comparison of our results with
those of the CDC surveys should be interpreted with caution,
however, as regions studied and sampling techniques were not
identical (for example, 21% of the isolates for the 1991 CDC sur-
vey were from New York and New Jersey, whereas for our study
31% were from this area).
The association of HIV infection with increased occurrence
of resistance to antituberculosis medications is logical based on
our understanding of the natural history of tuberculosis. In im-
munocompetent hosts, the interval from infection to disease is
usually one of many decades (21). Therefore, most HIV-negative
individuals who have developed active tuberculosis in the past
few years were infected with organisms during an era of low rates
of resistance. Progression from infection to disease occurs much
more rapidly in HIV-infected persons, with the time course tele-
scoped into months or a few years. Clinical and molecular
epidemiologic techniques have been used to demonstrate out-
breaks of primary tuberculosis within clusters of HIV-infected
persons (8-12), and that reinfection can occur in highly im-
munocompromised patients (22). Therefore patterns of resistance
to antituberculosis drugs in HIV-infected patients are likely to
be more reflective of recent trends in the community.
Resistance to antituberculosis medications has occurred since
their introduction, and is known to occur as a result of inap-
propriate use of these medications on the part of either the pro-
vider or the patient (23). Decreases in public health funding, poor
training of medical personnel in the treatment of tuberculosis,
lapses in infection control techniques, worsening socioeconomic
conditions, and the ongoing HIV epidemic have all combined
to increase the occurrence of tuberculosis and resistance to anti-
tuberculosis agents in the United States. While we have found
drug resistance to be high in the New York City area and of con-
cern in other regions of the country, we have also demonstrated
that the "battle" against tuberculosis has not been lost. In most
areas of the United States, over 95% of tuberculosis could be
well treated using currently available medications. Even in the
New YorkCity area, the majority of tuberculosis isolates in both
HIV-positive and HIV-negative persons are susceptible to two
or more primary drugs. We must take advantage of this oppor-
tunity to prevent further development of drug resistance and the
increased public health threat it poses by implementing aggres-
sive individual and public health measures including the use of
directly observed therapy (24), and the initiation of appropriate
four-drug therapy in all cases of proven or suspected disease (25).
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